Aktiesnakken — Juni 2012
-
Det er jo ikke som i gamle dage. Men min vurdering er at data er gode. Bivirkningsprofilen i orden. Efficacy interessant. Forsøget er lille. Vil Big pharma vente på readout på doseeskaleringsdelen?
-
Ja turin, der er gang i mabben p.t.
-
Jeg bliver kun kilden over cash.
-
ja det tror jeg godt vi kan
-
-
der er lidt cat stevens over ham Leoloo
-
du får lige lidt her lom
-
det bedste er at gå i debatten og se min copi af offentliggjorte slides i seneste genmab tråd
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind